TG Therapeutics, Inc. (TGTX)

Price$40.16

Value ScoreD

Growth ScoreA

Momentum ScoreB

Favorite Metrics

Price vs S&P 500 (26W)12.82%

Price vs S&P 500 (4W)-6.29%

VGM Score65.31

Market Capitalization$6.15B

P/E Ratio (Annual)13.75x

All Metrics

Book Value / Share (Quarterly)$3.81

P/TBV (Annual)3.26x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)504.86%

Cash Flow / Share (Quarterly)$-0.09

Price vs S&P 500 (YTD)26.56%

Gross Margin (TTM)83.05%

Net Profit Margin (TTM)65.95%

EPS (TTM)$2.87

10-Day Avg Trading Volume1.75M

EPS Excl Extra (TTM)$2.87

Revenue Growth (5Y)426.73%

EPS (Annual)$2.77

ROI (Annual)5.01%

Gross Margin (Annual)83.66%

Net Profit Margin (5Y Avg)-2631.07%

Cash / Share (Quarterly)$3.36

P/E Basic Excl Extra (TTM)13.31x

Revenue Growth QoQ (YoY)69.56%

P/E Normalized (Annual)13.75x

ROA (Last FY)4.05%

Revenue Growth TTM (YoY)81.26%

EBITD / Share (TTM)$0.87

ROE (5Y Avg)-112.83%

Operating Margin (TTM)20.04%

Cash Flow / Share (Annual)$-0.26

P/B Ratio10.54x

P/B Ratio (Quarterly)9.10x

Net Income / Employee (Annual)$1,120,700

EV / Revenue (TTM)9.21x

Net Interest Coverage (TTM)5.02x

ROA (TTM)42.77%

EPS Growth QoQ (YoY)297.43%

EV / EBITDA (TTM)45.94x

EPS Incl Extra (Annual)$2.77

Current Ratio (Annual)6.25x

Quick Ratio (Quarterly)5.12x

3-Month Avg Trading Volume1.95M

52-Week Price Return2.19%

P/E Incl Extra (TTM)13.31x

Revenue / Employee (TTM)$1,755,300

Tangible BV / Share (Quarterly)$1.17

P/S Ratio (Annual)9.98x

Asset Turnover (Annual)0.57x

52-Week High$44.65

Operating Margin (5Y Avg)-2590.34%

EPS Excl Extra (Annual)$2.77

CapEx CAGR (5Y)-9.73%

Tangible BV CAGR (5Y)-2.68%

26-Week Price Return20.75%

Quick Ratio (Annual)5.03x

13-Week Price Return38.34%

Total Debt / Equity (Annual)1.10x

Current Ratio (Quarterly)5.81x

Enterprise Value$6.45B

Revenue / Share Growth (5Y)393.83%

Asset Turnover (TTM)0.65x

Book Value / Share Growth (5Y)32.23%

Revenue / Employee (Annual)$1,544,600

Pretax Margin (Annual)17.43%

Cash / Share (Annual)$2.00

3-Month Return Std Dev55.67%

Gross Margin (5Y Avg)88.92%

Net Income / Employee (TTM)$1,157,600

ROE (Last FY)10.52%

Net Interest Coverage (Annual)5.42x

EPS Basic Excl Extra (Annual)$2.77

P/FCF (TTM)227.81x

Receivables Turnover (TTM)2.41x

Total Debt / Equity (Quarterly)1.28x

EPS Incl Extra (TTM)$2.87

Receivables Turnover (Annual)3.65x

ROI (TTM)51.38%

P/S Ratio (TTM)8.78x

Pretax Margin (5Y Avg)-2641.92%

Revenue / Share (Annual)$3.82

Tangible BV / Share (Annual)$1.17

Forward P/E19.71x

Price vs S&P 500 (52W)-22.18%

P/E Ratio (TTM)13.31x

EPS Growth TTM (YoY)1076.51%

Year-to-Date Return34.72%

5-Day Price Return7.35%

EPS Normalized (Annual)$2.77

ROA (5Y Avg)-48.82%

Net Profit Margin (Annual)72.56%

Month-to-Date Return5.85%

Cash Flow / Share (TTM)$-0.18

EBITD / Share (Annual)$0.76

Operating Margin (Annual)20.01%

LT Debt / Equity (Annual)1.10x

ROI (5Y Avg)-65.52%

P/E Excl Extra (TTM)13.31x

LT Debt / Equity (Quarterly)1.28x

EPS Basic Excl Extra (TTM)$2.87

P/TBV (Quarterly)3.26x

P/B Ratio (Annual)21.07x

Inventory Turnover (TTM)0.83x

Pretax Margin (TTM)17.46%

Book Value / Share (Annual)$1.43

Price vs S&P 500 (13W)30.08%

Beta1.67x

Revenue / Share (TTM)$4.38

ROE (TTM)87.36%

52-Week Low$25.28

vGradeD

gGradeA

mGradeB

vgmGradeB

Show chart for

Earnings Surprise History

Q1 260.18est. 0.30

Analyst Recommendations

Mar 2026

Apr 2026

May 2026

Jun 2026

3.93

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
TGTXTG Therapeutics, Inc.	D	A	B	$40.16
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

TG Therapeutics is a biopharmaceutical company specializing in B-cell disease treatments, with FDA-approved BRIUMVI (ublituximab-xiiy) for relapsing multiple sclerosis generating revenue primarily in the United States. The company is advancing a pipeline of early-stage therapies including TG-1701 (BTK inhibitor), Azer-Cel (CAR T-cell therapy), and TG-1801 (bispecific antibody) for various B-cell disorders.